|
1
|
Rudometova NB, Fando AA, Kisakova LA, Kisakov DN, Borgoyakova MB, Litvinova VR, Yakovlev VA, Tigeeva EV, Vahitov DI, Sharabrin SV, Shcherbakov DN, Evseenko VI, Ivanova KI, Gudymo AS, Ilyicheva TN, Marchenko VY, Ilyichev AA, Rudometov AP, Karpenko LI. Immunogenic and Protective Properties of Recombinant Hemagglutinin of Influenza A (H5N8) Virus. Vaccines (Basel) 2024; 12:143. [PMID: 38400127 PMCID: PMC10893068 DOI: 10.3390/vaccines12020143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 01/23/2024] [Accepted: 01/27/2024] [Indexed: 02/25/2024] Open
Abstract
In this study, we characterized recombinant hemagglutinin (HA) of influenza A (H5N8) virus produced in Chinese hamster ovary cells (CHO-K1s). Immunochemical analysis showed that the recombinant hemagglutinin was recognized by the serum of ferrets infected with influenza A (H5N8) virus, indicating that its antigenic properties were retained. Two groups of Balb/c mice were immunized with intramuscular injection of recombinant hemagglutinin or propiolactone inactivated A/Astrakhan/3212/2020 (H5N8) influenza virus. The results demonstrated that both immunogens induced a specific antibody response as determined by ELISA. Virus neutralization assay revealed that sera of immunized animals were able to neutralize A/turkey/Stavropol/320-01/2020 (H5N8) influenza virus-the average neutralizing titer was 2560. Immunization with both recombinant HA/H5 hemagglutinin and inactivated virus gave 100% protection against lethal H5N8 virus challenge. This study shows that recombinant HA (H5N8) protein may be a useful antigen candidate for developing subunit vaccines against influenza A (H5N8) virus with suitable immunogenicity and protective efficacy.
Collapse
Affiliation(s)
- Nadezhda B. Rudometova
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Anastasia A. Fando
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Lyubov A. Kisakova
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Denis N. Kisakov
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Mariya B. Borgoyakova
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Victoria R. Litvinova
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Vladimir A. Yakovlev
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Elena V. Tigeeva
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Danil I. Vahitov
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Sergey V. Sharabrin
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Dmitriy N. Shcherbakov
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Veronika I. Evseenko
- Institute of Solid State Chemistry and Mechanochemistry, Siberian Branch of Russian Academy of Sciences, Novosibirsk 630090, Novosibirsk Region, Russia;
| | - Ksenia I. Ivanova
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Andrei S. Gudymo
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Tatiana N. Ilyicheva
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Vasiliy Yu. Marchenko
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Alexander A. Ilyichev
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Andrey P. Rudometov
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| | - Larisa I. Karpenko
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector», Rospotrebnadzor, Koltsovo 630559, Novosibirsk Region, Russia (L.A.K.); (D.N.K.); (M.B.B.); (V.R.L.); (E.V.T.); (D.I.V.); (S.V.S.); (D.N.S.); (K.I.I.); (A.S.G.); (T.N.I.); (V.Y.M.); (A.A.I.); (A.P.R.); (L.I.K.)
| |
Collapse
|
|
2
|
Kisakov DN, Belyakov IM, Kisakova LA, Yakovlev VA, Tigeeva EV, Karpenko LI. The use of electroporation to deliver DNA-based vaccines. Expert Rev Vaccines 2024; 23:102-123. [PMID: 38063059 DOI: 10.1080/14760584.2023.2292772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Accepted: 12/05/2023] [Indexed: 12/19/2023]
Abstract
INTRODUCTION Nucleic acids represent a promising platform for creating vaccines. One disadvantage of this approach is its relatively low immunogenicity. Electroporation (EP) is an effective way to increase the DNA vaccines immunogenicity. However, due to the different configurations of devices used for EP, EP protocols optimization is required not only to enhance immunogenicity, but also to ensure greater safety and tolerability of the EP procedure. AREA COVERED An data analysis for recent years on the DNA vaccines delivery against viral and parasitic infections using EP was carried out. The study of various EP physical characteristics, such as frequency, pulse duration, pulse interval, should be considered along with the immunogenic construct design and the site of delivery of the vaccine, through the study of the immunogenic and protective characteristics of the latter. EXPERT OPINION Future research should focus on regulating the humoral and cellular response required for protection against infectious agents by modifying the EP protocol. Significant efforts will be directed to establishing the possibility of redirecting the immune response toward the Th1 or Th2 response by changing the EP physical parameters. It will allow for an individual selective approach during EP, depending on the pathogen type of an infectious disease.
Collapse
Affiliation(s)
- Denis N Kisakov
- Department of bioengineering, State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Novosibirsk region, Russia
| | - Igor M Belyakov
- Department of medico-biological disciplines, Moscow University for Industry and Finance "Synergy", Moscow, Russia
| | - Lubov A Kisakova
- Department of bioengineering, State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Novosibirsk region, Russia
| | - Vladimir A Yakovlev
- Department of bioengineering, State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Novosibirsk region, Russia
| | - Elena V Tigeeva
- Department of bioengineering, State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Novosibirsk region, Russia
| | - Larisa I Karpenko
- Department of bioengineering, State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Novosibirsk region, Russia
| |
Collapse
|
|
3
|
Kisakov DN, Antonets DV, Shaburova EV, Kisakova LA, Tigeeva EV, Yakovlev VA, Starostina EV, Borgoyakova MB, Protopopova EV, Svyatchenko VA, Loktev VB, Rudometov AP, Ilyichev AA, Nepomnyashchikh TS, Karpenko LI. DNA Vaccine Encoding the Artificial T-Cell Polyepitope Immunogen of Tick-Borne Encephalitis Virus. Bull Exp Biol Med 2023; 176:72-76. [PMID: 38091143 DOI: 10.1007/s10517-023-05970-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Indexed: 12/19/2023]
Abstract
A promising approach to the development of new means for preventing infection caused by tick-borne encephalitis virus can be DNA vaccines encoding polyepitope T-cell immunogens. A DNA vaccine pVAX-AG4-ub encoding an artificial polyepitope immunogen that includes cytotoxic and T-helper epitopes from the NS1, NS3, NS5, and E proteins of the tick-borne encephalitis virus has been obtained. The developed construct ensured the synthesis of the corresponding mRNAs in transfected eukaryotic cells. Immunization of mice with pVAX-AG4-ub induced the formation of a virus-specific T-cell response providing 50% protection from lethal infection with the virus.
Collapse
Affiliation(s)
- D N Kisakov
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
| | - D V Antonets
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - E V Shaburova
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - L A Kisakova
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - E V Tigeeva
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - V A Yakovlev
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - E V Starostina
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - M B Borgoyakova
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - E V Protopopova
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - V A Svyatchenko
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - V B Loktev
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - A P Rudometov
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - A A Ilyichev
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - T S Nepomnyashchikh
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - L I Karpenko
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| |
Collapse
|
|
4
|
Rudometova NB, Rudometov AP, Fando AA, Ushkalenko ND, Shcherbakov DN, Karpenko LI. Production and Study of Immunochemical Properties of Stabilized Env Trimer of Recombinant Form CRF63_02A6 of HIV-1. Bull Exp Biol Med 2023; 176:96-100. [PMID: 38093074 DOI: 10.1007/s10517-023-05978-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Indexed: 12/19/2023]
Abstract
Stabilized trimers of the HIV-1 envelope glycoprotein Env are capable of inducing a potent and sustained broadly neutralizing antibody response in laboratory animals and therefore are attractive targets for anti-HIV vaccine development. In this work, a stable producer of the trimer Env recombinant form CRF63_02A6 of HIV-1 was derived from the CHO-K1 cell line. Using immunochemical assays, the trimers synthesized in CHO-K1 cells were shown to be recognized by both monoclonal broadly neutralizing antibodies and sera from HIV-positive patients. The resulting trimers of the recombinant form CRF63_02A6 of HIV-1 can be used both for structural studies and as a candidate vaccine immunogen against HIV-1.
Collapse
Affiliation(s)
- N B Rudometova
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
| | - A P Rudometov
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - A A Fando
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - N D Ushkalenko
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - D N Shcherbakov
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - L I Karpenko
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| |
Collapse
|
|
5
|
Borgoyakova MB, Karpenko LI, Rudometov AP, Starostina EV, Zadorozhny AM, Kisakova LA, Kisakov DN, Sharabrin SV, Ilyichev AA, Bazhan SI. Artificial COVID-19 T-Cell Immunogen. Bull Exp Biol Med 2023; 175:804-809. [PMID: 37979020 DOI: 10.1007/s10517-023-05951-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Indexed: 11/19/2023]
Abstract
An artificial T-cell immunogen consisting of conserved fragments of different proteins of the SARS-CoV-2 virus and its immunogenic properties were studied in BALB/c mice. To create a T-cell immunogen, we used an approach based on the design of artificial antigens that combine many epitopes from the main proteins of the SARS-CoV-2 virus in the one molecule. The gene of the engineered immunogen protein was cloned as part of the pVAX1 plasmid in two versions: with an N-terminal ubiquitin and without it. The obtained plasmids were analyzed for their ability to provide the synthesis of the immunogen protein in vitro and in vivo. It has been shown that protein product of the created artificial genes is actively processed in HEK293T cells and induces cellular immunity in mice.
Collapse
Affiliation(s)
- M B Borgoyakova
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.
| | - L I Karpenko
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - A P Rudometov
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - E V Starostina
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - A M Zadorozhny
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - L A Kisakova
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - D N Kisakov
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - S V Sharabrin
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - A A Ilyichev
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| | - S I Bazhan
- State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia
| |
Collapse
|
|
6
|
Volosnikova EA, Merkuleva IA, Esina TI, Shcherbakov DN, Borgoyakova MB, Isaeva AA, Nesmeyanova VS, Volkova NV, Belenkaya SV, Zaykovskaya AV, Pyankov OV, Starostina EV, Zadorozhny AM, Zaitsev BN, Karpenko LI, Ilyichev AA, Danilenko ED. SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice. Vaccines (Basel) 2023; 11:vaccines11040808. [PMID: 37112720 PMCID: PMC10146165 DOI: 10.3390/vaccines11040808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2023] [Revised: 03/31/2023] [Accepted: 04/04/2023] [Indexed: 04/29/2023] Open
Abstract
Despite the rapid development and approval of several COVID vaccines based on the full-length spike protein, there is a need for safe, potent, and high-volume vaccines. Considering the predominance of the production of neutralizing antibodies targeting the receptor-binding domain (RBD) of S-protein after natural infection or vaccination, it makes sense to choose RBD as a vaccine immunogen. However, due to its small size, RBD exhibits relatively poor immunogenicity. Searching for novel adjuvants for RBD-based vaccine formulations is considered a good strategy for enhancing its immunogenicity. Herein, we assess the immunogenicity of severe acute respiratory syndrome coronavirus 2 RBD conjugated to a polyglucin:spermidine complex (PGS) and dsRNA (RBD-PGS + dsRNA) in a mouse model. BALB/c mice were immunized intramuscularly twice, with a 2-week interval, with 50 µg of RBD, RBD with Al(OH)3, or conjugated RBD. A comparative analysis of serum RBD-specific IgG and neutralizing antibody titers showed that PGS, PGS + dsRNA, and Al(OH)3 enhanced the specific humoral response in animals. There was no significant difference between the groups immunized with RBD-PGS + dsRNA and RBD with Al(OH)3. Additionally, the study of the T-cell response in animals showed that, unlike adjuvants, the RBD-PGS + dsRNA conjugate stimulates the production of specific CD4+ and CD8+ T cells in animals.
Collapse
Affiliation(s)
- Ekaterina A Volosnikova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Iuliia A Merkuleva
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Tatiana I Esina
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Dmitry N Shcherbakov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Mariya B Borgoyakova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Anastasiya A Isaeva
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Valentina S Nesmeyanova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Natalia V Volkova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Svetlana V Belenkaya
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Anna V Zaykovskaya
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Oleg V Pyankov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Ekaterina V Starostina
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Alexey M Zadorozhny
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Boris N Zaitsev
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Larisa I Karpenko
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Alexander A Ilyichev
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Elena D Danilenko
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| |
Collapse
|
|
7
|
Kisakova LA, Apartsin EK, Nizolenko LF, Karpenko LI. Dendrimer-Mediated Delivery of DNA and RNA Vaccines. Pharmaceutics 2023; 15:pharmaceutics15041106. [PMID: 37111593 PMCID: PMC10145063 DOI: 10.3390/pharmaceutics15041106] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 03/27/2023] [Accepted: 03/28/2023] [Indexed: 04/03/2023] Open
Abstract
DNA and RNA vaccines (nucleic acid-based vaccines) are a promising platform for vaccine development. The first mRNA vaccines (Moderna and Pfizer/BioNTech) were approved in 2020, and a DNA vaccine (Zydus Cadila, India), in 2021. They display unique benefits in the current COVID-19 pandemic. Nucleic acid-based vaccines have a number of advantages, such as safety, efficacy, and low cost. They are potentially faster to develop, cheaper to produce, and easier to store and transport. A crucial step in the technology of DNA or RNA vaccines is choosing an efficient delivery method. Nucleic acid delivery using liposomes is the most popular approach today, but this method has certain disadvantages. Therefore, studies are actively underway to develop various alternative delivery methods, among which synthetic cationic polymers such as dendrimers are very attractive. Dendrimers are three-dimensional nanostructures with a high degree of molecular homogeneity, adjustable size, multivalence, high surface functionality, and high aqueous solubility. The biosafety of some dendrimers has been evaluated in several clinical trials presented in this review. Due to these important and attractive properties, dendrimers are already being used to deliver a number of drugs and are being explored as promising carriers for nucleic acid-based vaccines. This review summarizes the literature data on the development of dendrimer-based delivery systems for DNA and mRNA vaccines.
Collapse
Affiliation(s)
- Lyubov A. Kisakova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Kol’tsovo, Russia
| | - Evgeny K. Apartsin
- CBMN, UMR 5248, CNRS, Bordeaux INP, University Bordeaux, F-33600 Pessac, France
| | - Lily F. Nizolenko
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Kol’tsovo, Russia
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Kol’tsovo, Russia
| |
Collapse
|
|
8
|
Shchelkunov SN, Yakubitskiy SN, Sergeev AA, Starostina EV, Titova KA, Pyankov SA, Shchelkunova GA, Borgoyakova MB, Zadorozhny AM, Orlova LA, Kisakov DN, Karpenko LI. Enhancing the Immunogenicity of Vaccinia Virus. Viruses 2022; 14:v14071453. [PMID: 35891430 PMCID: PMC9317313 DOI: 10.3390/v14071453] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Revised: 06/27/2022] [Accepted: 06/29/2022] [Indexed: 11/24/2022] Open
Abstract
The conventional live smallpox vaccine based on the vaccinia virus (VACV) cannot be widely used today because it is highly reactogenic. Therefore, there is a demand for designing VACV variants possessing enhanced immunogenicity, making it possible to reduce the vaccine dose and, therefore, significantly eliminate the pathogenic effect of the VACV on the body. In this study, we analyzed the development of the humoral and T cell-mediated immune responses elicited by immunizing mice with low-dose VACV variants carrying the mutant A34R gene (which increases production of extracellular virions) or the deleted A35R gene (whose protein product inhibits antigen presentation by the major histocompatibility complex class II). The VACV LIVP strain, which is used as a smallpox vaccine in Russia, and its recombinant variants LIVP-A34R*, LIVP-dA35R, and LIVP-A34R*-dA35R, were compared upon intradermal immunization of BALB/c mice at a dose of 104 pfu/animal. The strongest T cell-mediated immunity was detected in mice infected with the LIVP-A34R*-dA35R virus. The parental LIVP strain induced a significantly lower antibody level compared to the strains carrying the modified A34R and A35R genes. Simultaneous modification of the A34R gene and deletion of the A35R gene in VACV LIVP synergistically enhanced the immunogenic properties of the LIVP-A34R*-dA35R virus.
Collapse
|
|
9
|
Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Isaeva AA, Nesmeyanova VS, Volkova NV, Aripov VS, Shanshin DV, Karpenko LI, Belenkaya SV, Kazachinskaia EI, Volosnikova EA, Esina TI, Sergeev AA, Titova KA, Konyakhina YV, Zaykovskaya AV, Pyankov OV, Kolosova EA, Viktorina OE, Shelemba AA, Rudometov AP, Ilyichev AA. Are Hamsters a Suitable Model for Evaluating the Immunogenicity of RBD-Based Anti-COVID-19 Subunit Vaccines? Viruses 2022; 14:v14051060. [PMID: 35632800 PMCID: PMC9146860 DOI: 10.3390/v14051060] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 05/07/2022] [Accepted: 05/13/2022] [Indexed: 02/01/2023] Open
Abstract
Currently, SARS-CoV-2 spike receptor-binding-domain (RBD)-based vaccines are considered one of the most effective weapons against COVID-19. During the first step of assessing vaccine immunogenicity, a mouse model is often used. In this paper, we tested the use of five experimental animals (mice, hamsters, rabbits, ferrets, and chickens) for RBD immunogenicity assessments. The humoral immune response was evaluated by ELISA and virus-neutralization assays. The data obtained show hamsters to be the least suitable candidates for RBD immunogenicity testing and, hence, assessing the protective efficacy of RBD-based vaccines.
Collapse
Affiliation(s)
- Iuliia A. Merkuleva
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
- Correspondence: ; Tel.: +7-383-363-47-00 (ext. 2007)
| | - Mariya B. Borgoyakova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Anastasiya A. Isaeva
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Valentina S. Nesmeyanova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Natalia V. Volkova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Vazirbek S. Aripov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Daniil V. Shanshin
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Svetlana V. Belenkaya
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Elena I. Kazachinskaia
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Ekaterina A. Volosnikova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Tatiana I. Esina
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Alexandr A. Sergeev
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Kseniia A. Titova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Yulia V. Konyakhina
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Evgeniia A. Kolosova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
- Russian-American Anti-Cancer Center, Altai State University, 656049 Barnaul, Russia;
| | - Olesya E. Viktorina
- Russian-American Anti-Cancer Center, Altai State University, 656049 Barnaul, Russia;
| | - Arseniya A. Shelemba
- Federal Research Center of Fundamental and Translational Medicine, 630060 Novosibirsk, Russia;
| | - Andrey P. Rudometov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| |
Collapse
|
|
10
|
Borgoyakova MB, Karpenko LI, Rudometov AP, Volosnikova EA, Merkuleva IA, Starostina EV, Zadorozhny AM, Isaeva AA, Nesmeyanova VS, Shanshin DV, Baranov KO, Volkova NV, Zaitsev BN, Orlova LA, Zaykovskaya AV, Pyankov OV, Danilenko ED, Bazhan SI, Shcherbakov DN, Taranin AV, Ilyichev AA. Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in Mice. Int J Mol Sci 2022; 23:2188. [PMID: 35216301 PMCID: PMC8876144 DOI: 10.3390/ijms23042188] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 02/13/2022] [Accepted: 02/13/2022] [Indexed: 12/23/2022] Open
Abstract
Despite the fact that a range of vaccines against COVID-19 have already been created and are used for mass vaccination, the development of effective, safe, technological, and affordable vaccines continues. We have designed a vaccine that combines the recombinant protein and DNA vaccine approaches in a self-assembled particle. The receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 was conjugated to polyglucin:spermidine and mixed with DNA vaccine (pVAXrbd), which led to the formation of particles of combined coronavirus vaccine (CCV-RBD) that contain the DNA vaccine inside and RBD protein on the surface. CCV-RBD particles were characterized with gel filtration, electron microscopy, and biolayer interferometry. To investigate the immunogenicity of the combined vaccine and its components, mice were immunized with the DNA vaccine pVAXrbd or RBD protein as well as CCV-RBD particles. The highest antigen-specific IgG and neutralizing activity were induced by CCV-RBD, and the level of antibodies induced by DNA or RBD alone was significantly lower. The cellular immune response was detected only in the case of DNA or CCV-RBD vaccination. These results demonstrate that a combination of DNA vaccine and RBD protein in one construct synergistically increases the humoral response to RBD protein in mice.
Collapse
Affiliation(s)
- Mariya B. Borgoyakova
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Andrey P. Rudometov
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Ekaterina A. Volosnikova
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Iuliia A. Merkuleva
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Ekaterina V. Starostina
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Alexey M. Zadorozhny
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Anastasiya A. Isaeva
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Valentina S. Nesmeyanova
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Daniil V. Shanshin
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Konstantin O. Baranov
- Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Science, 630090 Novosibirsk, Russia; (K.O.B.); (A.V.T.)
| | - Natalya V. Volkova
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Boris N. Zaitsev
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Lyubov A. Orlova
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Elena D. Danilenko
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Sergei I. Bazhan
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Alexander V. Taranin
- Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Science, 630090 Novosibirsk, Russia; (K.O.B.); (A.V.T.)
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| |
Collapse
|
|
11
|
Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Shanshin DV, Rudometov AP, Karpenko LI, Belenkaya SV, Isaeva AA, Nesmeyanova VS, Kazachinskaia EI, Volosnikova EA, Esina TI, Zaykovskaya AV, Pyankov OV, Borisevich SS, Shelemba AA, Chikaev AN, Ilyichev AA. Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems. Vaccines (Basel) 2022; 10:vaccines10010096. [PMID: 35062757 PMCID: PMC8779843 DOI: 10.3390/vaccines10010096] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2021] [Revised: 01/02/2022] [Accepted: 01/04/2022] [Indexed: 01/05/2023] Open
Abstract
The receptor-binding domain (RBD) of the protein S SARS-CoV-2 is considered to be one of the appealing targets for developing a vaccine against COVID-19. The choice of an expression system is essential when developing subunit vaccines, as it ensures the effective synthesis of the correctly folded target protein, and maintains its antigenic and immunogenic properties. Here, we describe the production of a recombinant RBD protein using prokaryotic (pRBD) and mammalian (mRBD) expression systems, and compare the immunogenicity of prokaryotic and mammalian-expressed RBD using a BALB/c mice model. An analysis of the sera from mice immunized with both variants of the protein revealed that the mRBD expressed in CHO cells provides a significantly stronger humoral immune response compared with the RBD expressed in E.coli cells. A specific antibody titer of sera from mice immunized with mRBD was ten-fold higher than the sera from the mice that received pRBD in ELISA, and about 100-fold higher in a neutralization test. The data obtained suggests that mRBD is capable of inducing neutralizing antibodies against SARS-CoV-2.
Collapse
Affiliation(s)
- Iuliia A. Merkuleva
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
- Correspondence: ; Tel.: +7-383-363-47-00 (ext. 2007)
| | - Mariya B. Borgoyakova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Daniil V. Shanshin
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Andrey P. Rudometov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Svetlana V. Belenkaya
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Anastasiya A. Isaeva
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Valentina S. Nesmeyanova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Elena I. Kazachinskaia
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Ekaterina A. Volosnikova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Tatiana I. Esina
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Sophia S. Borisevich
- Laboratory of Chemical Physics, Ufa Institute of Chemistry, Ufa Federal Research Center, 450078 Ufa, Russia;
| | - Arseniya A. Shelemba
- Federal Research Center of Fundamental and Translational Medicine, 630060 Novosibirsk, Russia;
| | - Anton N. Chikaev
- Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia;
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| |
Collapse
|
|
12
|
Fomenko VV, Rudometova NB, Yarovaya OI, Rogachev AD, Fando AA, Zaykovskaya AV, Komarova NI, Shcherbakov DN, Pyankov OV, Pokrovsky AG, Karpenko LI, Maksyutov RA, Salakhutdinov NF. Synthesis and In Vitro Study of Antiviral Activity of Glycyrrhizin Nicotinate Derivatives against HIV-1 Pseudoviruses and SARS-CoV-2 Viruses. Molecules 2022; 27:295. [PMID: 35011529 PMCID: PMC8746574 DOI: 10.3390/molecules27010295] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 12/30/2021] [Accepted: 12/30/2021] [Indexed: 02/04/2023] Open
Abstract
When developing drugs against SARS-CoV-2, it is important to consider the characteristics of patients with different co-morbidities. People infected with HIV-1 are a particularly vulnerable group, as they may be at a higher risk than the general population of contracting COVID-19 with clinical complications. For such patients, drugs with a broad spectrum of antiviral activity are of paramount importance. Glycyrrhizinic acid (Glyc) and its derivatives are promising biologically active compounds for the development of such broad-spectrum antiviral agents. In this work, derivatives of Glyc obtained by acylation with nicotinic acid were investigated. The resulting preparation, Glycyvir, is a multi-component mixture containing mainly mono-, di-, tri- and tetranicotinates. The composition of Glycyvir was characterized by HPLC-MS/MS and its toxicity assessed in cell culture. Antiviral activity against three strains of SARS-CoV-2 was tested in vitro on Vero E6 cells by MTT assay. Glycyvir was shown to inhibit SARS-CoV-2 replication in vitro (IC502-8 μM) with an antiviral activity comparable to the control drug Remdesivir. In addition, Glycyvir exhibited marked inhibitory activity against HIV pseudoviruses of subtypes B, A6 and the recombinant form CRF63_02A (IC50 range 3.9-27.5 µM). The time-dependence of Glycyvir inhibitory activity on HIV pseudovirus infection of TZM-bl cells suggested that the compound interfered with virus entry into the target cell. Glycyvir is a promising candidate as an agent with low toxicity and a broad spectrum of antiviral action.
Collapse
Affiliation(s)
- Vladislav V. Fomenko
- Department of Medicinal Chemistry, N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave. 9, 630090 Novosibirsk, Russia; (V.V.F.); (A.D.R.); (N.I.K.); (N.F.S.)
| | - Nadezhda B. Rudometova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (N.B.R.); (A.V.Z.); (D.N.S.); (O.V.P.); (L.I.K.); (R.A.M.)
| | - Olga I. Yarovaya
- Department of Medicinal Chemistry, N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave. 9, 630090 Novosibirsk, Russia; (V.V.F.); (A.D.R.); (N.I.K.); (N.F.S.)
- Zelman Institute for Medicine and Psychology, Novosibirsk State University, Pirogov Str. 1, 630090 Novosibirsk, Russia; (A.A.F.); (A.G.P.)
| | - Artem D. Rogachev
- Department of Medicinal Chemistry, N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave. 9, 630090 Novosibirsk, Russia; (V.V.F.); (A.D.R.); (N.I.K.); (N.F.S.)
- Zelman Institute for Medicine and Psychology, Novosibirsk State University, Pirogov Str. 1, 630090 Novosibirsk, Russia; (A.A.F.); (A.G.P.)
| | - Anastasia A. Fando
- Zelman Institute for Medicine and Psychology, Novosibirsk State University, Pirogov Str. 1, 630090 Novosibirsk, Russia; (A.A.F.); (A.G.P.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (N.B.R.); (A.V.Z.); (D.N.S.); (O.V.P.); (L.I.K.); (R.A.M.)
| | - Nina I. Komarova
- Department of Medicinal Chemistry, N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave. 9, 630090 Novosibirsk, Russia; (V.V.F.); (A.D.R.); (N.I.K.); (N.F.S.)
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (N.B.R.); (A.V.Z.); (D.N.S.); (O.V.P.); (L.I.K.); (R.A.M.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (N.B.R.); (A.V.Z.); (D.N.S.); (O.V.P.); (L.I.K.); (R.A.M.)
| | - Andrey G. Pokrovsky
- Zelman Institute for Medicine and Psychology, Novosibirsk State University, Pirogov Str. 1, 630090 Novosibirsk, Russia; (A.A.F.); (A.G.P.)
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (N.B.R.); (A.V.Z.); (D.N.S.); (O.V.P.); (L.I.K.); (R.A.M.)
| | - Rinat A. Maksyutov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (N.B.R.); (A.V.Z.); (D.N.S.); (O.V.P.); (L.I.K.); (R.A.M.)
| | - Nariman F. Salakhutdinov
- Department of Medicinal Chemistry, N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave. 9, 630090 Novosibirsk, Russia; (V.V.F.); (A.D.R.); (N.I.K.); (N.F.S.)
- Zelman Institute for Medicine and Psychology, Novosibirsk State University, Pirogov Str. 1, 630090 Novosibirsk, Russia; (A.A.F.); (A.G.P.)
| |
Collapse
|
|
13
|
Borgoyakova MB, Karpenko LI, Rudometov AP, Shanshin DV, Isaeva AA, Nesmeyanova VS, Volkova NV, Belenkaya SV, Murashkin DE, Shcherbakov DN, Volosnikova EA, Starostina EV, Orlova LA, Danilchenko NV, Zaikovskaya AV, Pyankov OV, Ilyichev AA. Immunogenic Properties of the DNA Construct Encoding the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. Mol Biol 2021; 55:889-898. [PMID: 34955558 PMCID: PMC8682036 DOI: 10.1134/s0026893321050046] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Revised: 04/19/2021] [Accepted: 04/20/2021] [Indexed: 11/22/2022]
Abstract
The development of preventive vaccines became the first order task in the COVID-19 pandemic caused by SARS-CoV-2. This paper reports the construction of the pVAX-RBD plasmid containing the Receptor-Binding Domain (RBD) of the S protein and a unique signal sequence 176 which promotes target protein secretion into the extracellular space thereby increasing the efficiency of humoral immune response activation. A polyglucine-spermidine conjugate (PGS) was used to deliver pVAX-RBD into the cells. The comparative immunogenicity study of the naked pVAX-RBD and pVAX-RBD enclosed in the PGS envelope showed that the latter was more efficient in inducing an immune response in the immunized mice. In particular, RBD-specific antibody titers were shown in ELISA to be no higher than 1 : 1000 in the animals from the pVAX-RBD group and 1 : 42 000, in the pVAX-RBD-PGS group. The pVAX-RBD‒PGS construct effectively induced cellular immune response. Using ELISpot, it has been demonstrated that splenocytes obtained from the immunized animals effectively produced INF-γ in response to stimulation with the S protein-derived peptide pool. The results suggest that the polyglucine-spermidine conjugate-enveloped pVAX-RBD construct may be considered as a promising DNA vaccine against COVID-19.
Collapse
Affiliation(s)
- M B Borgoyakova
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - L I Karpenko
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - A P Rudometov
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - D V Shanshin
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - A A Isaeva
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia.,World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program for the Development of Genetic Technologies, Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - V S Nesmeyanova
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia.,World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program for the Development of Genetic Technologies, Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - N V Volkova
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - S V Belenkaya
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - D E Murashkin
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - D N Shcherbakov
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia.,World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program for the Development of Genetic Technologies, Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - E A Volosnikova
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - E V Starostina
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - L A Orlova
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - N V Danilchenko
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - A V Zaikovskaya
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - O V Pyankov
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| | - A A Ilyichev
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, 630559 Koltsovo, Novosibirsk oblast Russia
| |
Collapse
|
|
14
|
Borgoyakova MB, Karpenko LI, Rudometov AP, Shanshin DV, Isaeva AA, Nesmeyanova VS, Volkova NV, Belenkaya SV, Murashkin DE, Shcherbakov DN, Volosnikova EA, Starostina EV, Orlova LA, Danilchenko NV, Zaikovskaya AV, Pyankov OV, Ilyichev AA. [Immunogenic Properties of the DNA Construct Encoding the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein]. Mol Biol (Mosk) 2021; 55:987-998. [PMID: 34837703 DOI: 10.31857/s0026898421060045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Accepted: 04/20/2021] [Indexed: 11/24/2022]
Abstract
The development of preventive vaccines became the first order task in the COVID-19 pandemic caused by SARS-CoV-2. This paper reports the construction of the pVAX-RBD plasmid containing the Receptor-Binding Domain (RBD) of the S protein and a unique signal sequence 176 which promotes target protein secretion into the extracellular space thereby increasing the efficiency of humoral immune response activation. A polyglucine-spermidine conjugate (PGS) was used to deliver pVAX-RBD into the cells. The comparative immunogenicity study of the naked pVAX-RBD and pVAX-RBD enclosed in the PGS envelope showed that the latter was more efficient in inducing an immune response in the immunized mice. In particular, RBD-specific antibody titers were shown in ELISA to be no higher than 1 : 1000 in the animals from the pVAX-RBD group and 1 : 42000, in the pVAX-RBD-PGS group. The pVAX-RBD-PGS construct effectively induced cellular immune response. Using ELISpot, it has been demonstrated that splenocytes obtained from the immunized animals effectively produced INF-y in response to stimulation with the S protein-derived peptide pool. The results suggest that the polyglucine-spermidine conjugate-enveloped pVAX-RBD construct may be considered as a promising DNA vaccine against COVID-19.
Collapse
Affiliation(s)
- M B Borgoyakova
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia.,
| | - L I Karpenko
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| | - A P Rudometov
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| | - D V Shanshin
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| | - A A Isaeva
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia.,World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program for the Development of Genetic Technologies, Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsovo, Novosibirsk Oblast, 630559 Russia
| | - V S Nesmeyanova
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia.,World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program for the Development of Genetic Technologies, Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsovo, Novosibirsk Oblast, 630559 Russia
| | - N V Volkova
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| | - S V Belenkaya
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| | - D E Murashkin
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| | - D N Shcherbakov
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia.,World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program for the Development of Genetic Technologies, Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsovo, Novosibirsk Oblast, 630559 Russia
| | - E A Volosnikova
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| | - E V Starostina
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| | - L A Orlova
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| | - N V Danilchenko
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| | - A V Zaikovskaya
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| | - O V Pyankov
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| | - A A Ilyichev
- Vector State Research Center of Virology and Biotechnology, Russian Federal State Agency for Health and Consumer Rights Surveillance, Koltsavo, Novosibirsk Oblast, 630559 Russia
| |
Collapse
|
|
15
|
Chikaev AN, Chikaev AN, Rudometov AP, Merkulyeva YA, Karpenko LI. Phage display as a tool for identifying HIV-1 broadly neutralizing antibodies. Vavilovskii Zhurnal Genet Selektsii 2021; 25:562-572. [PMID: 34595378 PMCID: PMC8453360 DOI: 10.18699/vj21.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 03/14/2021] [Accepted: 03/22/2021] [Indexed: 11/19/2022] Open
Abstract
Combinatorial biology methods offer a good solution for targeting interactions of specif ic molecules
by a high-throughput screening and are widely used for drug development, diagnostics, identif ication of novel
monoclonal antibodies, search for linear peptide mimetics of discontinuous epitopes for the development of
immunogens or vaccine components. Among all currently available techniques, phage display remains one of
the most popular approaches. Despite being a fairly old method, phage display is still widely used for studying
protein-protein, peptide-protein and DNA-protein interactions due to its relative simplicity and versatility. Phage
display allows highly representative libraries of peptides, proteins or their fragments to be created. Each phage
particle in a library displays peptides or proteins fused to its coat protein and simultaneously carries the DNA
sequence encoding the displayed peptide/protein in its genome. The biopanning procedure allows isolation of
specif ic clones for almost any target, and due to the physical link between the genotype and the phenotype of
recombinant phage particles it is possible to determine the structure of selected molecules. Phage display technology
continues to play an important role in HIV research. A major obstacle to the development of an effective
HIV vaccine is an extensive genetic and antigenic variability of the virus. According to recent data, in order to provide
protection against HIV infection, the so-called broadly neutralizing antibodies that are cross-reactive against
multiple viral strains of HIV must be induced, which makes the identif ication of such antibodies a key area of HIV
vaccinology. In this review, we discuss the use of phage display as a tool for identif ication of HIV-specif ic antibodies
with broad neutralizing activity. We provide an outline of phage display technology, brief ly describe the
design of antibody phage libraries and the affinity selection procedure, and discuss the biology of HIV-1-specif ic
broadly neutralizing antibodies. Finally, we summarize the studies aimed at identif ication of broadly neutralizing
antibodies using various types of phage libraries.
Collapse
Affiliation(s)
| | - A N Chikaev
- Institute of Molecular and Cellular Biology of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - A P Rudometov
- State Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk region, Russia
| | - Yu A Merkulyeva
- State Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk region, Russia
| | - L I Karpenko
- State Research Center of Virology and Biotechnology "Vector", Rospotrebnadzor, Koltsovo, Novosibirsk region, Russia
| |
Collapse
|
|
16
|
Rudometova NB, Shcherbakova NS, Shcherbakov DN, Mishenova EV, Delgado E, Ilyichev AA, Karpenko LI, Thomson MM. Genetic Diversity and Drug Resistance Mutations in Reverse Transcriptase and Protease Genes of HIV-1 Isolates from Southwestern Siberia. AIDS Res Hum Retroviruses 2021; 37:716-723. [PMID: 33677988 DOI: 10.1089/aid.2020.0225] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The analysis of a pol gene fragment encoding protease and part of reverse transcriptase was carried out for 55 sera collected in 2016 and 2018 from HIV-1-infected patients diagnosed in 2014-2018 living in the south of Western Siberia, Russia: Altai Territory (n = 11), Republic of Altai (n = 15), Kemerovo region (n = 18), and Novosibirsk region (n = 11). CRF63_02A was the dominant genetic form (>70%) in the Altai Territory and Kemerovo and Novosibirsk regions, with subsubtype A6 comprising <30% of samples. In the Altai Republic, subsubtype A6 was predominant (53%), with 33% of viruses belonging to CRF63_02A. Four CRF63_02A/A6 unique recombinant forms were identified in the Altai Territory, Kemerovo Region, and the Altai Republic. A majority (11 of 15) of CRF63_02A viruses from Kemerovo were grouped in a cluster. Antiretroviral (ARV) drug resistance mutations were found in 6 (14%) of 43 drug-naive patients. This study provides new insights in HIV-1 molecular epidemiology and prevalence of transmitted ARV drug resistance mutations in Southwestern Siberia.
Collapse
Affiliation(s)
- Nadezhda B. Rudometova
- Department of Bioengineering, State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Russia
| | - Nadezhda S. Shcherbakova
- Department of Bioengineering, State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Russia
| | - Dmitry N. Shcherbakov
- Department of Bioengineering, State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Russia
| | - Elena V. Mishenova
- Budgetary Health Care Institution of the Republic of Altai “Center for the Prevention and Control of AIDS”, Gorno-Altaysk, Russia
| | - Elena Delgado
- HIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain
| | - Alexander A. Ilyichev
- Department of Bioengineering, State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Russia
| | - Larisa I. Karpenko
- Department of Bioengineering, State Research Center of Virology and Biotechnology “Vector”, Koltsovo, Russia
| | - Michael M. Thomson
- HIV Biology and Variability Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
|
17
|
Starostina EV, Sharabrin SV, Antropov DN, Stepanov GA, Shevelev GY, Lemza AE, Rudometov AP, Borgoyakova MB, Rudometova NB, Marchenko VY, Danilchenko NV, Chikaev AN, Bazhan SI, Ilyichev AA, Karpenko LI. Construction and Immunogenicity of Modified mRNA-Vaccine Variants Encoding Influenza Virus Antigens. Vaccines (Basel) 2021; 9:452. [PMID: 34063689 PMCID: PMC8147809 DOI: 10.3390/vaccines9050452] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Revised: 04/15/2021] [Accepted: 04/29/2021] [Indexed: 01/08/2023] Open
Abstract
Nucleic acid-based influenza vaccines are a promising platform that have recently and rapidly developed. We previously demonstrated the immunogenicity of DNA vaccines encoding artificial immunogens AgH1, AgH3, and AgM2, which contained conserved fragments of the hemagglutinin stem of two subtypes of influenza A-H1N1 and H3N2-and conserved protein M2. Thus, the aim of this study was to design and characterize modified mRNA obtained using the above plasmid DNA vaccines as a template. To select the most promising protocol for creating highly immunogenic mRNA vaccines, we performed a comparative analysis of mRNA modifications aimed at increasing its translational activity and decreasing toxicity. We used mRNA encoding a green fluorescent protein (GFP) as a model. Eight mRNA-GFP variants with different modifications (M0-M7) were obtained using the classic cap(1), its chemical analog ARCA (anti-reverse cap analog), pseudouridine (Ψ), N6-methyladenosine (m6A), and 5-methylcytosine (m5C) in different ratios. Modifications M2, M6, and M7, which provided the most intensive fluorescence of transfected HEK293FT cells were used for template synthesis when mRNA encoded influenza immunogens AgH1, AgH3, and AgM2. Virus specific antibodies were registered in groups of animals immunized with a mix of mRNAs encoding AgH1, AgH3, and AgM2, which contained either ARCA (with inclusions of 100% Ψ and 20% m6A (M6)) or a classic cap(1) (with 100% substitution of U with Ψ (M7)). M6 modification was the least toxic when compared with other mRNA variants. M6 and M7 RNA modifications can therefore be considered as promising protocols for designing mRNA vaccines.
Collapse
Affiliation(s)
- Ekaterina V. Starostina
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Sergei V. Sharabrin
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Denis N. Antropov
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia; (D.N.A.); (G.A.S.); (G.Y.S.); (A.E.L.)
| | - Grigory A. Stepanov
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia; (D.N.A.); (G.A.S.); (G.Y.S.); (A.E.L.)
| | - Georgiy Yu. Shevelev
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia; (D.N.A.); (G.A.S.); (G.Y.S.); (A.E.L.)
| | - Anna E. Lemza
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia; (D.N.A.); (G.A.S.); (G.Y.S.); (A.E.L.)
| | - Andrey P. Rudometov
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Mariya B. Borgoyakova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Nadezhda B. Rudometova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Vasiliy Yu. Marchenko
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Natalia V. Danilchenko
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Anton N. Chikaev
- Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia;
| | - Sergei I. Bazhan
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (S.V.S.); (A.P.R.); (M.B.B.); (N.B.R.); (V.Y.M.); (N.V.D.); (S.I.B.); (A.A.I.); (L.I.K.)
| |
Collapse
|
|
18
|
Karpenko LI, Rudometov AP, Sharabrin SV, Shcherbakov DN, Borgoyakova MB, Bazhan SI, Volosnikova EA, Rudometova NB, Orlova LA, Pyshnaya IA, Zaitsev BN, Volkova NV, Azaev MS, Zaykovskaya AV, Pyankov OV, Ilyichev AA. Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate. Vaccines (Basel) 2021; 9:76. [PMID: 33494530 PMCID: PMC7910849 DOI: 10.3390/vaccines9020076] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 01/15/2021] [Accepted: 01/19/2021] [Indexed: 12/12/2022] Open
Abstract
One of the key stages in the development of mRNA vaccines is their delivery. Along with liposome, other materials are being developed for mRNA delivery that can ensure both the safety and effectiveness of the vaccine, and also facilitate its storage and transportation. In this study, we investigated the polyglucin:spermidine conjugate as a carrier of an mRNA-RBD vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. The conditions for the self-assembling of mRNA-PGS complexes were optimized, including the selection of the mRNA:PGS charge ratios. Using dynamic and electrophoretic light scattering it was shown that the most monodisperse suspension of nanoparticles was formed at the mRNA:PGS charge ratio equal to 1:5. The average hydrodynamic particles diameter was determined, and it was confirmed by electron microscopy. The evaluation of the zeta potential of the investigated complexes showed that the particles surface charge was close to the zero point. This may indicate that the positively charged PGS conjugate has completely packed the negatively charged mRNA molecules. It has been shown that the packaging of mRNA-RBD into the PGS envelope leads to increased production of specific antibodies with virus-neutralizing activity in immunized BALB/c mice. Our results showed that the proposed polycationic polyglucin:spermidine conjugate can be considered a promising and safe means to the delivery of mRNA vaccines, in particular mRNA vaccines against SARS-CoV-2.
Collapse
Affiliation(s)
- Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Andrey P. Rudometov
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Sergei V. Sharabrin
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Mariya B. Borgoyakova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Sergei I. Bazhan
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Ekaterina A. Volosnikova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Nadezhda B. Rudometova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Lyubov A. Orlova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Inna A. Pyshnaya
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, 630090 Novosibirsk, Russia;
| | - Boris N. Zaitsev
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Natalya V. Volkova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Mamedyar Sh. Azaev
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk, Russia; (A.P.R.); (S.V.S.); (D.N.S.); (M.B.B.); (S.I.B.); (E.A.V.); (N.B.R.); (L.A.O.); (B.N.Z.); (N.V.V.); (M.S.A.); (A.V.Z.); (O.V.P.); (A.A.I.)
| |
Collapse
|
|
19
|
Ilyichev AA, Orlova LA, Sharabrin SV, Karpenko LI. mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development. Vavilovskii Zhurnal Genet Selektsii 2020; 24:802-807. [PMID: 33959697 PMCID: PMC8094037 DOI: 10.18699/vj20.676] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
After the genome sequence of SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2) was published and the number of infected people began to increase rapidly, many global companies began to develop a vaccine. Almost all known approaches to vaccine design were applied for this purpose, including inactivated viruses, mRNA and DNA-vaccines, vaccines based on various viral vectors, synthetically generated peptides and recombinant proteins produced in cells of insects and mammals. This review considers one of the promising vaccine platforms based on messenger RNA. Until recent years, mRNA-vaccination was out of practical implementation due to high sensitivity to nuclease degradation and consequent instability of drugs based on mRNA. Latest technological advances significantly mitigated the problems of low immunogenicity, instability, and difficulties in RNA-vaccine delivery. It is worth noting that mRNA-vaccines can efficiently activate both components of the immune system, i. e. T-cell and humoral responses. The essential advantage of mRNAvaccines includes fast, inexpensive, scalable and uniform production providing a large output of desirable products in vitro. Synthesis and purification processes significantly simplify the process technology of mRNA drugs with injectable purity. Thus, mRNA production via in vitro transcription is more advantageous as compared with DNA-vaccines since it is a chemical process without the use of cells. mRNA techniques make it possible to pass all the phases of vaccine development much faster in comparison with the production of vaccines based on inactivated viruses or recombinant proteins. This property is critically important when designing vaccines against viral pathogens as the main problem of disease control includes a time gap between an epidemic and vaccine development. This paper discusses studies on the development of vaccines against coronaviruses including SARS-CoV-2 with special attention to the mRNA technique.
Collapse
Affiliation(s)
- A A Ilyichev
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, Russia
| | - L A Orlova
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, Russia
| | - S V Sharabrin
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, Russia
| | - L I Karpenko
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, Russia
| |
Collapse
|
|
20
|
Karpenko LI, Apartsin EK, Dudko SG, Starostina EV, Kaplina ON, Antonets DV, Volosnikova EA, Zaitsev BN, Bakulina AY, Venyaminova AG, Ilyichev AA, Bazhan SI. Cationic Polymers for the Delivery of the Ebola DNA Vaccine Encoding Artificial T-Cell Immunogen. Vaccines (Basel) 2020; 8:vaccines8040718. [PMID: 33271964 PMCID: PMC7760684 DOI: 10.3390/vaccines8040718] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 11/23/2020] [Accepted: 11/27/2020] [Indexed: 11/16/2022] Open
Abstract
Background: According to current data, an effective Ebola virus vaccine should induce both humoral and T-cell immunity. In this work, we focused our efforts on methods for delivering artificial T-cell immunogen in the form of a DNA vaccine, using generation 4 polyamidoamine dendrimers (PAMAM G4) and a polyglucin:spermidine conjugate (PG). Methods: Optimal conditions were selected for obtaining complexes of previously developed DNA vaccines with cationic polymers. The sizes, mobility and surface charge of the complexes with PG and PAMAM 4G have been determined. The immunogenicity of the obtained vaccine constructs was investigated in BALB/c mice. Results: It was shown that packaging of DNA vaccine constructs both in the PG envelope and the PAMAM 4G envelope results in an increase in their immunogenicity as compared with the group of mice immunized with the of vector plasmid pcDNA3.1 (a negative control). The highest T-cell responses were shown in mice immunized with complexes of DNA vaccines with PG and these responses significantly exceeded those in the groups of animals immunized with both the combination of naked DNAs and the combination DNAs coated with PAMAM 4G. In the group of animals immunized with complexes of the DNA vaccines with PAMAM 4G, no statistical differences were found in the ability to induce T-cell responses, as compared with the group of mice immunized with the combination of naked DNAs. Conclusions: The PG conjugate can be considered as a promising and safe means to deliver DNA-based vaccines. The use of PAMAM requires further optimization.
Collapse
Affiliation(s)
- Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk Region, Russia; (S.G.D.); (E.V.S.); (O.N.K.); (D.V.A.); (E.A.V.); (B.N.Z.); (A.Y.B.); (A.A.I.)
- Correspondence: (L.I.K.); (S.I.B.); Tel.: +7-383-363-47-00 (ext. 2001) (L.I.K. & S.I.B.)
| | - Evgeny K. Apartsin
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, 630090 Novosibirsk, Russia; (E.K.A.); (A.G.V.)
- Department of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
- Laboratoire de Chimie de Coordination, CNRS, 31077 Toulouse, France
| | - Sergei G. Dudko
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk Region, Russia; (S.G.D.); (E.V.S.); (O.N.K.); (D.V.A.); (E.A.V.); (B.N.Z.); (A.Y.B.); (A.A.I.)
| | - Ekaterina V. Starostina
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk Region, Russia; (S.G.D.); (E.V.S.); (O.N.K.); (D.V.A.); (E.A.V.); (B.N.Z.); (A.Y.B.); (A.A.I.)
| | - Olga N. Kaplina
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk Region, Russia; (S.G.D.); (E.V.S.); (O.N.K.); (D.V.A.); (E.A.V.); (B.N.Z.); (A.Y.B.); (A.A.I.)
| | - Denis V. Antonets
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk Region, Russia; (S.G.D.); (E.V.S.); (O.N.K.); (D.V.A.); (E.A.V.); (B.N.Z.); (A.Y.B.); (A.A.I.)
| | - Ekaterina A. Volosnikova
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk Region, Russia; (S.G.D.); (E.V.S.); (O.N.K.); (D.V.A.); (E.A.V.); (B.N.Z.); (A.Y.B.); (A.A.I.)
| | - Boris N. Zaitsev
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk Region, Russia; (S.G.D.); (E.V.S.); (O.N.K.); (D.V.A.); (E.A.V.); (B.N.Z.); (A.Y.B.); (A.A.I.)
| | - Anastasiya Yu. Bakulina
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk Region, Russia; (S.G.D.); (E.V.S.); (O.N.K.); (D.V.A.); (E.A.V.); (B.N.Z.); (A.Y.B.); (A.A.I.)
- Department of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
| | - Aliya G. Venyaminova
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, 630090 Novosibirsk, Russia; (E.K.A.); (A.G.V.)
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk Region, Russia; (S.G.D.); (E.V.S.); (O.N.K.); (D.V.A.); (E.A.V.); (B.N.Z.); (A.Y.B.); (A.A.I.)
| | - Sergei I. Bazhan
- State Research Center of Virology and Biotechnology “Vector”, Koltsovo, 630559 Novosibirsk Region, Russia; (S.G.D.); (E.V.S.); (O.N.K.); (D.V.A.); (E.A.V.); (B.N.Z.); (A.Y.B.); (A.A.I.)
- Correspondence: (L.I.K.); (S.I.B.); Tel.: +7-383-363-47-00 (ext. 2001) (L.I.K. & S.I.B.)
| |
Collapse
|
|
21
|
Bazhan SI, Antonets DV, Starostina EV, Ilyicheva TN, Kaplina ON, Marchenko VY, Volkova OY, Bakulina AY, Karpenko LI. In silico design of influenza a virus artificial epitope-based T-cell antigens and the evaluation of their immunogenicity in mice. J Biomol Struct Dyn 2020; 40:3196-3212. [PMID: 33222632 DOI: 10.1080/07391102.2020.1845978] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The polyepitope strategy is promising approach for successfully creating a broadly protective flu vaccine, which targets T-lymphocytes (both CD4+ and CD8+) to recognise the most conserved epitopes of viral proteins. In this study, we employed a computer-aided approach to develop several artificial antigens potentially capable of evoking immune responses to different virus subtypes. These antigens included conservative T-cell epitopes of different influenza A virus proteins. To design epitope-based antigens we used experimentally verified information regarding influenza virus T-cell epitopes from the Immune Epitope Database (IEDB) (http://www.iedb.org). We constructed two "human" and two "murine" variants of polyepitope antigens. Amino acid sequences of target polyepitope antigens were designed using our original TEpredict/PolyCTLDesigner software. Immunogenic and protective features of DNA constructs encoding "murine" target T-cell immunogens were studied in BALB/c mice. We showed that mice groups immunised with a combination of computer-generated "murine" DNA immunogens had a 37.5% survival rate after receiving a lethal dose of either A/California/4/2009 (H1N1) virus or A/Aichi/2/68 (H3N2) virus, while immunisation with live flu H1N1 and H3N2 vaccine strains provided protection against homologous viruses and failed to protect against heterologous viruses. These results demonstrate that mechanisms of cross-protective immunity may be associated with the stimulation of specific T-cell responses. This study demonstrates that our computer-aided approach may be successfully used for rational designing artificial polyepitope antigens capable of inducing virus-specific T-lymphocyte responses and providing partial protection against two different influenza virus subtypes.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Sergei I Bazhan
- Theoretical Department, State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region, Russia
| | - Denis V Antonets
- Theoretical Department, State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region, Russia
| | - Ekaterina V Starostina
- Bioengineering Department, State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region, Russia
| | - Tatyana N Ilyicheva
- Department of zoonotic infections and Influenza, State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region, Russia
| | - Olga N Kaplina
- Bioengineering Department, State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region, Russia
| | - Vasiliy Yu Marchenko
- Department of zoonotic infections and Influenza, State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region, Russia
| | - Olga Yu Volkova
- Immunogenetics laboratory, Institute of Molecular and Cellular Biology of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - Anastasiya Yu Bakulina
- Theoretical Department, State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region, Russia.,Laboratory of structural bioinformatics and molecular modeling, Novosibirsk State University, Novosibirsk, Russia
| | - Larisa I Karpenko
- Bioengineering Department, State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region, Russia
| |
Collapse
|
|
22
|
Rudometov AP, Chikaev AN, Rudometova NB, Antonets DV, Lomzov AA, Kaplina ON, Ilyichev AA, Karpenko LI. Artificial Anti-HIV-1 Immunogen Comprising Epitopes of Broadly Neutralizing Antibodies 2F5, 10E8, and a Peptide Mimic of VRC01 Discontinuous Epitope. Vaccines (Basel) 2019; 7:vaccines7030083. [PMID: 31390770 PMCID: PMC6789618 DOI: 10.3390/vaccines7030083] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Revised: 07/24/2019] [Accepted: 07/30/2019] [Indexed: 01/05/2023] Open
Abstract
The construction of artificial proteins using conservative B-cell and T-cell epitopes is believed to be a promising approach for a vaccine design against diverse viral infections. This article describes the development of an artificial HIV-1 immunogen using a polyepitope immunogen design strategy. We developed a recombinant protein, referred to as nTBI, that contains epitopes recognized by broadly neutralizing HIV-1 antibodies (bNAbs) combined with Th-epitopes. This is a modified version of a previously designed artificial protein, TBI (T- and B-cell epitopes containing Immunogen), carrying four T- and five B-cell epitopes from HIV-1 Env and Gag proteins. To engineer the nTBI molecule, three B-cell epitopes of the TBI protein were replaced with the epitopes recognized by broadly neutralizing HIV-1 antibodies 10E8, 2F5, and a linear peptide mimic of VRC01 epitope. We showed that immunization of rabbits with the nTBI protein elicited antibodies that recognize HIV-1 proteins and were able to neutralize Env-pseudotyped SF162.LS HIV-1 strain (tier 1). Competition assay revealed that immunization of rabbits with nTBI induced mainly 10E8-like antibodies. Our findings support the use of nTBI protein as an immunogen with predefined favorable antigenic properties.
Collapse
Affiliation(s)
- Andrey P Rudometov
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia.
| | - Anton N Chikaev
- Institute of Molecular and Cellular Biology of the Siberian Branch of the Russian Academy of Sciences, 8/2 Lavrentiev Avenue Novosibirsk, Novosibirsk 630090, Russia.
| | - Nadezhda B Rudometova
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Denis V Antonets
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Alexander A Lomzov
- Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences, 8 Lavrentiev Avenue, Novosibirsk 630090, Russia
| | - Olga N Kaplina
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Alexander A Ilyichev
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia
| | - Larisa I Karpenko
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region 630559, Russia.
| |
Collapse
|
|
23
|
Shcherbakova NS, Chikaev AN, Rudometov AP, Shcherbakov DN, Il'ichev AA, Karpenko LI. Characteristics of Artificial Immunogens Containing Peptide Mimotopes of HIV-1 Epitopes Recognized by Monoclonal Antibodies 2F5 and 2G12. Bull Exp Biol Med 2019; 167:259-262. [PMID: 31243678 DOI: 10.1007/s10517-019-04504-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Indexed: 11/29/2022]
Abstract
The paper describes construction of TBI-based recombinant proteins TBI-2F5 and TBI-2G12 that contain peptide mimotopes of HIV-1 epitopes recognized by broadly neutralizing antibodies 2F5 and 2G12, respectively. The capacity of the immunogens to induce neutralizing antibodies was evaluated. The sera of BALB/c mice immunized with recombinant proteins TBI, TBI-2F5, and TBI-2G12 neutralized HIV-1 env-pseudoviruses. Moreover, pooled serum from mice immunized with TBI-2F5 and TBI-2G12 neutralized env-pseudoviruses of HIV-1 subtype B more effectively than individual sera.
Collapse
Affiliation(s)
- N S Shcherbakova
- State Research Center of Virology and Biotechnology Vector, Federal Service on Surveillance for Consumer Rights Protection and Human Well-Being (Rospotrebnadzor), Kol'tsovo, Novosibirsk region, Russia.
| | - A N Chikaev
- Institute of Molecular and Cellular Biology, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia
| | - A P Rudometov
- State Research Center of Virology and Biotechnology Vector, Federal Service on Surveillance for Consumer Rights Protection and Human Well-Being (Rospotrebnadzor), Kol'tsovo, Novosibirsk region, Russia
| | - D N Shcherbakov
- State Research Center of Virology and Biotechnology Vector, Federal Service on Surveillance for Consumer Rights Protection and Human Well-Being (Rospotrebnadzor), Kol'tsovo, Novosibirsk region, Russia
| | - A A Il'ichev
- State Research Center of Virology and Biotechnology Vector, Federal Service on Surveillance for Consumer Rights Protection and Human Well-Being (Rospotrebnadzor), Kol'tsovo, Novosibirsk region, Russia
| | - L I Karpenko
- State Research Center of Virology and Biotechnology Vector, Federal Service on Surveillance for Consumer Rights Protection and Human Well-Being (Rospotrebnadzor), Kol'tsovo, Novosibirsk region, Russia
| |
Collapse
|
|
24
|
Karpenko LI, Lebedev LR, Bazhan SI, Korneev DV, Zaitsev BB, Ilyichev AA. Visualization of CombiHIVvac Vaccine Particles Using Electron Microscopy. AIDS Res Hum Retroviruses 2017; 33:323-324. [PMID: 27996294 PMCID: PMC5372770 DOI: 10.1089/aid.2016.0140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/29/2022] Open
Affiliation(s)
- Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector,” Koltsovo, Russia
| | - Leonid R. Lebedev
- State Research Center of Virology and Biotechnology “Vector,” Koltsovo, Russia
| | - Sergei I. Bazhan
- State Research Center of Virology and Biotechnology “Vector,” Koltsovo, Russia
| | - Denis V. Korneev
- State Research Center of Virology and Biotechnology “Vector,” Koltsovo, Russia
| | - Boris B. Zaitsev
- State Research Center of Virology and Biotechnology “Vector,” Koltsovo, Russia
| | | |
Collapse
|
|
25
|
Shcherbakova NS, Shcherbakov DN, Bakulina AY, Karpenko LI, Ryzhikov AB, Ilyichev AA. Artificial polyepitope HIV-1 immunogen containing mimotope of 2F5 epitope. Protein Pept Lett 2016; 23:159-68. [PMID: 26655727 DOI: 10.2174/0929866523666151211115746] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2015] [Revised: 12/07/2015] [Accepted: 12/11/2015] [Indexed: 11/22/2022]
Abstract
Constructing a vaccine against HIV-1, able to induce production of broadly neutralizing antibodies, is crucial. We report here the selection and characterization of RDWSFDRWSLSEFWL peptide mimotope that binds specifically to bNAbs 2F5. The peptide mimotope was selected from 15-mer phage-displayed peptide library by using Mab 2F5 as the selecting agent. The most abundant RDWSFDRWSLSEFWL peptide was inserted into a carrier, an artificial polyepitope immunogen - TBI (T- and B-cell immunogen). TBI-2F5 polyepitope immunogen that includes the mimotope of 2F5 epitope was constructed. It was shown that sera of mice immunized with TBI-2F5 protein recognized TBI protein as well as RDWSFDRWSLSEFWL peptide. The capacity of sera of immunized mice to neutralize HIV-1 was demonstrated using subtype B env-pseudoviruses of HIV-1 QH0692.42 and PVO.4. Based on these results, we conclude that peptide mimotope of 2F5 epitope RDWSFDRWSLSEFWL can be an essential component for a successful HIV-vaccine.
Collapse
|
|
26
|
Nazarkina ZK, Kharkova MV, Antonets DV, Morozkin ES, Bazhan SI, Karpenko LI, Vlassov VV, Ilyichev AA, Laktionov PP. Erratum to: Design of Polyepitope DNA Vaccine against Breast Carcinoma Cells and Analysis of Its Expression in Dendritic Cells. Bull Exp Biol Med 2016; 160:727. [PMID: 27037926 DOI: 10.1007/s10517-016-3261-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Zh K Nazarkina
- Institute of Chemical Biology and Fundamental Medicine Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia. .,Meshalkin Novosibirsk State Research Institute of Circulation Pathology, Novosibirsk, Russia.
| | - M V Kharkova
- Institute of Chemical Biology and Fundamental Medicine Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia
| | - D V Antonets
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Russia
| | - E S Morozkin
- Institute of Chemical Biology and Fundamental Medicine Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia
| | - S I Bazhan
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Russia
| | - L I Karpenko
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Russia
| | - V V Vlassov
- Institute of Chemical Biology and Fundamental Medicine Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia
| | - A A Ilyichev
- Institute of Chemical Biology and Fundamental Medicine Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.,State Research Center of Virology and Biotechnology "Vector", Koltsovo, Russia
| | - P P Laktionov
- Institute of Chemical Biology and Fundamental Medicine Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.,Meshalkin Novosibirsk State Research Institute of Circulation Pathology, Novosibirsk, Russia
| |
Collapse
|
|
27
|
Nazarkina ZK, Khar'kova MV, Antonets DV, Morozkin ES, Bazhan SI, Karpenko LI, Vlasov VV, Ilyichev AA, Laktionov PP. Design of Polyepitope DNA Vaccine against Breast Carcinoma Cells and Analysis of Its Expression in Dendritic Cells. Bull Exp Biol Med 2016; 160:486-90. [PMID: 26915653 DOI: 10.1007/s10517-016-3203-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Indexed: 01/07/2023]
Abstract
Polyepitope DNA vaccine inducing T-cell-mediated immune response against cancer-specific antigens is a promising tool for selective elimination of tumor cells. Breast cancer-specific polyepitope DNA vaccine was designed using TEpredict and PolyCTLDesigner software on the basis of immunogenic peptides of HER2 and Mammaglobin-1 (Mam) tumor antigens. LPS-free preparations of plasmid DNA encoding polyepitope T-cell antigen and full-length copies of HER2 and Mam antigens were obtained. TaqMan-PCR systems for evaluation of the expression of immunogens in cells were created. The protocol of vaccine DNA delivery into dendritic cells was optimized. Expression of the target immunogens in dendritic cells derived from human peripheral blood mononuclear fraction after transfection with plasmid DNA preparations is demonstrated.
Collapse
Affiliation(s)
- Zh K Nazarkina
- Institute of Chemical Biology and Basic Medicine, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia. .,E. N. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Novosibirsk, Russia.
| | - M V Khar'kova
- Institute of Chemical Biology and Basic Medicine, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia
| | - D V Antonets
- Vector State Research Center of Virology and Biotechnology, Koltsovo, Russia
| | - E S Morozkin
- Vector State Research Center of Virology and Biotechnology, Koltsovo, Russia
| | - S I Bazhan
- Vector State Research Center of Virology and Biotechnology, Koltsovo, Russia
| | - L I Karpenko
- Vector State Research Center of Virology and Biotechnology, Koltsovo, Russia
| | - V V Vlasov
- Institute of Chemical Biology and Basic Medicine, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia
| | - A A Ilyichev
- Institute of Chemical Biology and Basic Medicine, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.,Vector State Research Center of Virology and Biotechnology, Koltsovo, Russia
| | - P P Laktionov
- Institute of Chemical Biology and Basic Medicine, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.,Vector State Research Center of Virology and Biotechnology, Koltsovo, Russia
| |
Collapse
|
|
28
|
|
|
29
|
Chikaev AN, Bakulina AY, Burdick RC, Karpenko LI, Pathak VK, Ilyichev AA. Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01. PLoS One 2015; 10:e0120847. [PMID: 25785734 PMCID: PMC4364665 DOI: 10.1371/journal.pone.0120847] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2014] [Accepted: 01/26/2015] [Indexed: 12/24/2022] Open
Abstract
The ability to induce anti-HIV-1 antibodies that can neutralize a broad spectrum of viral isolates from different subtypes seems to be a key requirement for development of an effective HIV-1 vaccine. The epitopes recognized by the most potent broadly neutralizing antibodies that have been characterized are largely discontinuous. Mimetics of such conformational epitopes could be potentially used as components of a synthetic immunogen that can elicit neutralizing antibodies. Here we used phage display technology to identify peptide motifs that mimic the epitope recognized by monoclonal antibody VRC01, which is able to neutralize up to 91% of circulating primary isolates. Three rounds of biopanning were performed against 2 different phage peptide libraries for this purpose. The binding specificity of selected phage clones to monoclonal antibody VRC01 was estimated using dot blot analysis. The putative peptide mimics exposed on the surface of selected phages were analyzed for conformational and linear homology to the surface of HIV-1 gp120 fragment using computational analysis. Corresponding peptides were synthesized and checked for their ability to interfere with neutralization activity of VRC01 in a competitive inhibition assay. One of the most common peptides selected from 12-mer phage library was found to partially mimic a CD4-binding loop fragment, whereas none of the circular C7C-mer peptides was able to mimic any HIV-1 domains. However, peptides identified from both the 12-mer and C7C-mer peptide libraries showed rescue of HIV-1 infectivity in the competitive inhibition assay. The identification of epitope mimics may lead to novel immunogens capable of inducing broadly reactive neutralizing antibodies.
Collapse
Affiliation(s)
- Anton N. Chikaev
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Novosibirsk region, 630559, Russia
- * E-mail:
| | - Anastasiya Yu. Bakulina
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Novosibirsk region, 630559, Russia
| | - Ryan C. Burdick
- HIV Drug Resistance Program, National Cancer Institute-Frederick, Viral Mutation Section, Frederick, Maryland, 21702, United States of America
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Novosibirsk region, 630559, Russia
| | - Vinay K. Pathak
- HIV Drug Resistance Program, National Cancer Institute-Frederick, Viral Mutation Section, Frederick, Maryland, 21702, United States of America
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Novosibirsk region, 630559, Russia
| |
Collapse
|
|
30
|
Reguzova AY, Karpenko LI, Mechetina LV, Belyakov IM. Peptide-MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development. Expert Rev Vaccines 2014; 14:69-84. [PMID: 25373312 DOI: 10.1586/14760584.2015.962520] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The use of MHC multimers allows precise and direct detecting and analyzing of antigen-specific T-cell populations and provides new opportunities to characterize T-cell responses in humans and animals. MHC-multimers enable us to enumerate specific T-cells targeting to viral, tumor and vaccine antigens with exceptional sensitivity and specificity. In the field of HIV/SIV immunology, this technique provides valuable information about the frequencies of HIV- and SIV-specific CD8(+) cytotoxic T lymphocytes (CTLs) in different tissues and sites of infection, AIDS progression, and pathogenesis. Peptide-MHC multimer technology remains a very sensitive tool in detecting virus-specific T -cells for evaluation of the immunogenicity of vaccines against HIV-1 in preclinical trials. Moreover, it helps to understand how immune responses are formed following vaccination in the dynamics from priming point until T-cell memory is matured. Here we review a diversity of peptide-MHC class I multimer applications for fundamental immunological studies in different aspects of HIV/SIV infection and vaccine development.
Collapse
Affiliation(s)
- Alena Y Reguzova
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, 630559, Russia
| | | | | | | |
Collapse
|
|
31
|
Abstract
RV144 clinical trial was modestly effective in preventing HIV infection. New alternative approaches are needed to design improved HIV-1 vaccines and their delivery strategies. One of these approaches is construction of synthetic polyepitope HIV-1 immunogen using protective T- and B-cell epitopes that can induce broadly neutralizing antibodies and responses of cytotoxic (CD8(+) CTL) and helpers (CD4(+) Th) T-lymphocytes. This approach seems to be promising for designing of new generation of vaccines against HIV-1, enables in theory to cope with HIV-1 antigenic variability, focuses immune responses on protective determinants and enables to exclude from the vaccine compound that can induce autoantibodies or antibodies enhancing HIV-1 infectivity. Herein, the authors will focus on construction and rational design of polyepitope T-cell HIV-1 immunogens and their delivery, including: advantages and disadvantages of existing T-cell epitope prediction methods; features of organization of polyepitope immunogens, which can generate high-level CD8(+) and CD4(+) T-lymphocyte responses; the strategies to optimize efficient processing, presentation and immunogenicity of polyepitope constructs; original software to design polyepitope immunogens; and delivery vectors as well as mucosal strategies of vaccination. This new knowledge may bring us a one step closer to developing an effective T-cell vaccine against HIV-1, other chronic viral infections and cancer.
Collapse
Affiliation(s)
- Larisa I Karpenko
- State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, 630559, Russia
| | | | | | | |
Collapse
|
|
32
|
Karpenko LI, Scherbakova NS, Chikaev AN, Tumanova OY, Lebedev LR, Shalamova LA, Pyankova OG, Ryzhikov AB, Ilyichev AA. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12. Mol Immunol 2012; 50:193-9. [PMID: 22341130 DOI: 10.1016/j.molimm.2012.01.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2011] [Revised: 12/21/2011] [Accepted: 01/12/2012] [Indexed: 01/22/2023]
Abstract
A major goal in HIV-1 vaccine research is to develop an immunogen that can elicit broadly neutralizing antibodies that efficiently neutralize a wide range of the HIV-1 subtypes. Using biopanning procedure we have selected linear peptide VGAFGSFYRLSVLQS mimicking the structure of discontinuous binding sites of broadly neutralizing antibodies 2G12 from phage peptide library. As a protein carrier, we used the earlier designed artificial polyepitope immunogen named TBI (T- and B-cell immunogen), which comprises B-cell and T-helper epitopes from the HIV-1 Env and Gag proteins. On the base of selected peptide mimotope VGAFGSFYRLSVLQS the artificial protein TBI-2g12 was constructed and its immunogenic properties was investigated. It was shown that the TBI-2g12 as well as the original TBI induces antibodies that recognize HIV-1 proteins and TBI protein using ELISA and immunoblotting. However only anti-TBI-2g12 serum recognized the synthetic peptide mimotope VGAFGSFYRLSVLQS, whereas the antibodies against original TBI don't recognize it. The neutralization assay demonstrated that serum antibodies of the mice immunized with TBI-2g12 possess virus neutralizing activity. The addition of selected peptide leads to inhibition neutralizing activity of anti- TBI-2g12 serum. We conclude from these results that immunogen TBI-2g12 containing the selected peptide VGAFGSFYRLSVLQS elicits HIV-1 neutralizing antibodies during immunization. Our data suggest that this immunogen may be useful in designing effective HIV-vaccine candidates.
Collapse
Affiliation(s)
- Larisa I Karpenko
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Novosibirsk Region, 630559 Russia
| | | | | | | | | | | | | | | | | |
Collapse
|
|
33
|
Shcherbakova NS, Chikaev AN, Karpenko LI, Il'ichev AA. [The impact of the antibody 2F5 biotinylation on the selection of the peptides from combinatorial phage library]. Mol Gen Mikrobiol Virusol 2012:20-25. [PMID: 22702140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The impact of monoclonal antibodies (mAb) biotinylation on the output and the repertoire of selected peptides in the biopanning procedure were tested. A comparative analysis of the peptides selected from phage library using the biotinylated and non-biotinylated mAb 2F5 was performed. It was shown that the output of peptides homologous to the native epitope was 1.7-fold higher for biotinylated antibodies, whereas the binding capacity of the selected phages with mAb 2F5 in ELISA was higher in the case of using non-biotinylated antibodies. It should be noted that the phages exposing peptides, which have 4-5 amino acid sequence similarity with the native epitope, demonstrate the highest binding affinity. The phages that expose peptides with 3 amino acid sequence similarity demonstrate different binding affinity: from the smallest to the largest. Based on the obtained data, it is safe to suggest that the rational biopanning may proceed in accordance with the task.
Collapse
|
|
34
|
Karpenko LI, Danilenko AV, Bazhan SI, Danilenko ED, Sysoeva GM, Kaplina ON, Volkova OY, Oreshkova SF, Ilyichev AA. Attenuated Salmonella enteritidis E23 as a vehicle for the rectal delivery of DNA vaccine coding for HIV-1 polyepitope CTL immunogen. Microb Biotechnol 2011; 5:241-50. [PMID: 21895998 PMCID: PMC3815784 DOI: 10.1111/j.1751-7915.2011.00291.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
This study is focusing on elucidation of the capacity of attenuated Salmonella enteritidis E23 (cya, crp) to serve as a vehicle for the rectal delivery of the DNA vaccine. Earlier for creation HIV‐1 candidate DNA vaccine we have designed the polyepitope protein TCI (T‐cell immunogen), which comprises over 80 CTL epitopes from subtype A, B and C HIV‐1 proteins. The gene coding for TCI protein was used to construct the eukaryotic expression plasmid pcDNA‐TCI. The attenuated S. enteritidis E23 was transformed by electroporation with recombinant plasmid pcDNA‐TCI and the expression of the TCI gene was determined in vitro and in vivo. BALB/c mice were rectally immunized with S. enteritidis E23/pcDNA‐TCI (108 cfu) twice at 4 week interval. Bacteria were not pathogenic for mice and spontaneously eliminated from mice spleen and liver to 60 days post the immunization. Detectable antibodies were generated in 2 weeks after immunization and their level increased after second immunization. The results of INF‐γ ELISpot show that mice immunized with S. enteritidis E23/pcDNA‐TCI elicited HIV‐specific cellular immune response. This study demonstrates that attenuated S. enteritidis E23 is an effective live vector for rectal delivery of the DNA vaccine pcDNA‐TCI to generate humoral and T‐cellular responses against HIV‐1.
Collapse
Affiliation(s)
- Larisa I Karpenko
- State Research Center of Virology and Biotechnology 'Vector', 630559 Koltsovo, Novosibirsk, Russia.
| | | | | | | | | | | | | | | | | |
Collapse
|
|
35
|
Karpenko LI, Mechetina LV, Reguzova AI. [MHC-multimers and their application in studies of antiviral immune response]. Zh Mikrobiol Epidemiol Immunobiol 2011:112-119. [PMID: 21598627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Application of main histocompatibility complex tetrames (MHC-tetramers) for antigen specific T-cells detection and analysis coupled with flow cytometry opened new opportunities for T-cell response analysis. MHC-multimers allow the detection of T-cells against viral, cancer and vaccine antigens with exceptional sensitivity and specificity. This approach has become the "gold standard" for quantative analysis of T-cell immune response. Certain aspects of analysis using MHC-tetramer are examined, and importance of this approach in T-cell response efficacy evaluation in anti-HIV vaccine trials as well as in HIV positive patients are discussed.
Collapse
|
|
36
|
Bazhan SI, Karpenko LI, Ilyicheva TN, Belavin PA, Seregin SV, Danilyuk NK, Antonets DV, Ilyichev AA. Rational design based synthetic polyepitope DNA vaccine for eliciting HIV-specific CD8+ T cell responses. Mol Immunol 2010; 47:1507-15. [PMID: 20189249 DOI: 10.1016/j.molimm.2010.01.020] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2009] [Revised: 01/05/2010] [Accepted: 01/24/2010] [Indexed: 11/30/2022]
Abstract
Advances in defining HIV-1 CD8+ T cell epitopes and understanding endogenous MHC class I antigen processing enable the rational design of polyepitope vaccines for eliciting broadly targeted CD8+ T cell responses to HIV-1. Here we describe the construction and comparison of experimental DNA vaccines consisting of ten selected HLA-A2 epitopes from the major HIV-1 antigens Env, Gag, Pol, Nef, and Vpr. The immunogenicity of designed gene constructs was assessed after double DNA prime, single vaccinia virus boost immunization of HLA-A2 transgenic mice. We compared a number of parameters including different strategies for fusing ubiquitin to the polyepitope and including spacer sequences between epitopes to optimize proteasome liberation and TAP transport. It was demonstrated that the vaccine construct that induced in vitro the largest number of [peptide-MHC class I] complexes was also the most immunogenic in the animal experiments. This most immunogenic vaccine construct contained the N-terminal ubiquitin for targeting the polyepitope to the proteasome and included both proteasome liberation and TAP transport optimized spacer sequences that flanked the epitopes within the polyepitope construct. The immunogenicity of determinants was strictly related to their affinities for HLA-A2. Our finding supports the concept of rational vaccine design based on detailed knowledge of antigen processing.
Collapse
Affiliation(s)
- S I Bazhan
- State Research Center of Virology and Biotechnology Vector, Koltsovo, Novosibirsk Region, 630559 Russia.
| | | | | | | | | | | | | | | |
Collapse
|
|
37
|
Bazhan SI, Karpenko LI, Lebedev LR, Uzhachenko RV, Belavin PA, Eroshkin AM, Ilyichev AA. A synergistic effect of a combined bivalent DNA–protein anti-HIV-1 vaccine containing multiple T- and B-cell epitopes of HIV-1 proteins. Mol Immunol 2008; 45:661-9. [PMID: 17869341 DOI: 10.1016/j.molimm.2007.07.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2007] [Revised: 07/09/2007] [Accepted: 07/10/2007] [Indexed: 10/22/2022]
Abstract
Immunogenic properties of the combined vaccine CombiHIVvac, comprising polyepitope HIV-1 immunogens, one being the artificial polyepitope protein TBI, containing the T- and B-cell epitopes from Env and Gag proteins, and the DNA vaccine construct pcDNA-TCI coding for the artificial protein TCI, carrying over 80 T-cell epitopes (both CD4+ CTL and CD8+ Th) from Env, Gag, Pol, and Nef proteins, are studied in this work. The data reported demonstrate clearly that a combination of two B- and T-cell immunogens (TBI and TCI) in one construct results in a synergistic increase in the antibody response to both TBI protein and the proteins from HIV-1 lysate. The level of antibodies induced by immunization with the constructs containing either immunogen alone (TBI protein or the plasmid pcDNA-TCI) was significantly lower as compared to that induced by the combined vaccine. The analysis performed suggests that the presence of CD4+ T-helper epitopes, which can be presented by MHC class II, in the protein TCI may be the main reason underlying the increased synthesis of antibodies to TBI protein due to a CD4-mediated stimulation of B-cell proliferation and differentiation.
Collapse
Affiliation(s)
- Sergei I Bazhan
- Theoretical Department, State Research Center of Virology and Biotechnology Vector, 630559 Koltsovo, Novosibirsk Region, Russia.
| | | | | | | | | | | | | |
Collapse
|
|
38
|
Karpenko LI, Bazhan SI, Eroshkin AM, Lebedev LR, Uzhachenko RV, Nekrasova NA, Plyasunova OA, Belavin PA, Seregin SV, Danilyuk NK, Danilenko ED, Zaitsev BN, Masicheva VI, Ilyichev AA, Sandakhchiev LS. CombiHIV vac vaccine which contains polypepitope B-and T-cell immunogens of HIV-1. DOKL BIOCHEM BIOPHYS 2007; 413:65-7. [PMID: 17546955 DOI: 10.1134/s160767290702007x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- L I Karpenko
- Vector State Scientific Center of Virology and Biotechnology, Kol'tsovo, Novosibirsk oblast, 630559, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
39
|
Karpenko LI, Ilyichev AA, Eroshkin AM, Lebedev LR, Uzhachenko RV, Nekrasova NA, Plyasunova OA, Belavin PA, Seregin SV, Danilyuk NK, Zaitsev BN, Danilenko ED, Masycheva VI, Bazhan SI. Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine design, immunogenicity and toxicity studies. Vaccine 2007; 25:4312-23. [PMID: 17418918 DOI: 10.1016/j.vaccine.2007.02.058] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2006] [Revised: 02/13/2007] [Accepted: 02/20/2007] [Indexed: 10/23/2022]
Abstract
We have previously described designing of polyepitope immunogens TBI and TCI, to stimulate the humoral and cellular immune responses to HIV-1. Here, immunogens TBI and TCI were used to create new vaccine construct named CombiHIVvac (Combined HIV-1 vaccine). CombiHIVvac is a virus-like particles (VLP) containing the DNA vaccine pcDNA-TCI as a core encapsulated within a spermidine-polyglucin-TBI conjugate. The immunogenic and toxic properties of the candidate vaccine CombiHIVvac have been studied. CombiHIVvac induces a strong humoral and CTL responses in mice; the antibodies are highly specific and are able to neutralize HIV-1 in vitro. Preclinical study demonstrated that CombiHIVvac does not cause long-term changes in physiological, biochemical and morphological parameters in immunized animals and thus can be recommended for clinical trials.
Collapse
MESH Headings
- AIDS Vaccines/adverse effects
- AIDS Vaccines/chemistry
- AIDS Vaccines/immunology
- Animals
- Blotting, Western
- Cells, Cultured
- Cytokines/biosynthesis
- Enzyme-Linked Immunosorbent Assay
- Epitopes/genetics
- Epitopes/immunology
- HIV Antibodies/blood
- HIV-1/immunology
- Humans
- Lymphocytes/immunology
- Mice
- Mice, Inbred BALB C
- Models, Animal
- Neutralization Tests
- Vaccines, DNA/adverse effects
- Vaccines, DNA/chemistry
- Vaccines, DNA/immunology
- Vaccines, Virosome/adverse effects
- Vaccines, Virosome/chemistry
- Vaccines, Virosome/immunology
Collapse
Affiliation(s)
- Larisa I Karpenko
- State Research Center of Virology and Biotechnology Vector, 630559 Koltsovo, Novosibirsk region, Russia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
40
|
Veremeĭko TA, Lebedev LR, Chikaev NA, Il'ichev AA, Karpenko LI. [Humoral immune response of BALB/c mice immunized with chimer HBcAg proteins carrying the epitopes of surface hepatic B virus protein]. Vopr Virusol 2007; 52:40-5. [PMID: 17338233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
Chimeric HBcAg proteins carrying epitopes from surface hepatitis B virus (HBV) protein (regions 137-147 a.o. HBsAg, 27-37 a.a. region preS1 and 131-145 a.a. region preS2) have been early constructed. This paper presents the data of an investigation of a humoral immune response in mice immunized with obtained by chimeric HBcAg proteins. The findings suggest that the chimeric HBcAg proteins carrying the epitopes of surface HBV protein are able to induce an immune response to both inserted epitopes and carrying protein (HBcAg). Immunization with a mixture of chimeric proteins taken in equivalent quantities induces the synthesis of antibodies to hybrid proteins. The use of aluminum hydroxide considerably enhances a humoral immune response during immunization with chimeric bovine proteins.
Collapse
|
|
41
|
Il'ichev AA, Karpenko LI, Nekrasova NA, Lebedev LR, Ignat'ev GM, Agafonov AP, Belavin PA, Seregin SS, Daniliuk NK, Bazhan SI. [Different systems of delivery of HIV-1 DNA vaccine encoding the multiepitope CTL-immunogene]. Vestn Ross Akad Med Nauk 2005:41-4. [PMID: 15715155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
We used, within the case study, virus-like particles (VLP) and attenuated strains of salmonella for the delivery of HIV-1 DNA vaccine encoding the multiepitope CTL-immunogene. The immunogenicity of the thus obtained vaccine constructions was comparatively analyzed. All constructions were shown to be able of inducing, in immunized animals, both the specific T-cell responses and the synthesis of virus-specific antibodies. The lowest level of immune response was registered in animals immunized by "naked" plasmid DNA. The delivery by plasmid DNA involving VLP or the attenuated strain of salmonella enhances the efficiency of the DNA-vaccine presentation to the immune system.
Collapse
|
|
42
|
Maksimov NL, Bukin EK, Agafonov AP, Neverov AA, Karpenko LI, Il'ichev AA, Ignat'ev GM. [Anti-measles DNA-immunization in experiment: immunogenicity and safety]. Vopr Virusol 2005; 50:4-9. [PMID: 15747863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
The plasmid DNA pCDNA3.1-H encoding the N-terminal sequence of the measles hemagglutinin (H) protein was constructed. Virus-specific particles (VSP) containing the plasmid DNA pCDNA3.1-H coated by the spermidine-polyglucin complex. The mice were immunized by VSP. ELISA, HAIT and immunoblot showed a shaping specific humoral response. The sera of immunized animals were proven to neutralize the wild strain of the NOV96 measles virus. The formation of the specific cell immunity was confirmed by erythrocyte proliferation assay and ELISpot. PCR was used to detect the presence of the plasmid DNA in different intestines and tissues of animals after a single immunization. It was not detected at any time interval in the brain, liver, thymus and blood. And it was present on days 7 and 14 in the red bone marrow, spleen, muscular tissue, lungs and fatty tissue. On day 21 the plasmid DNA was not detected in any of the investigated organs.
Collapse
|
|
43
|
Karpenko LI, Veremeĭko TA, Tumanova OI, Pika IS, Chikaev NA, Melamed NV, Nagaĭtseva NV, Kuvshinov VN, Riazankin IA, Il'ichev AA. [Presentation of HIV epitopes by HBcAg]. Vestn Ross Akad Med Nauk 2005:37-40. [PMID: 15715154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
The hepatitis B core antigen (HBcAg) was used to present the HIV epitopes and mimics selected by phage display. The HIV epitopes were inserted into the el loop of HBcAg. The influence of insertions on the ability of chimeric HBcAg to assemble itself was studied. Special soft was made use of to detect the regularities between certain physical-and-chemical properties of amine-acid residua (belonging to an inserted alien peptide) and the presence or loss of the ability of HBcAg to assemble itself. Recommendations are provided of how to overcome difficulties related with the presentation of alien epitopes.
Collapse
|
|
44
|
Karpenko LI, Nekrasova NA, Ilyichev AA, Lebedev LR, Ignatyev GM, Agafonov AP, Zaitsev BN, Belavin PA, Seregin SV, Danilyuk NK, Babkina IN, Bazhan SI. Comparative analysis using a mouse model of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CTL-immunogen. Vaccine 2004; 22:1692-9. [PMID: 15068852 DOI: 10.1016/j.vaccine.2003.09.050] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Two systems have been examined for delivery of DNA-vaccine encoding a HIV-1 polyepitope CTL-immunogen (TCI). One is intended for i.m. injection and is in the form of an artificial virus like particle containing eukaryotic expression plasmid pcDNA-TCI encapsulated within a spermidine-polyglucin conjugate. The other is intended for mucosal immunization and is based on attenuated Salmonella typhimurium strain 7207, which can deliver pcDNA-TCI directly into professional antigen-presenting cells (APC). After immunization, the artificial VLP and recombinant Salmonella induced an enhanced HIV specific serum antibody, proliferative and CTL responses compared to those induced by naked pcDNA-TCI. The most significant responses were produced when pcDNA-TCI was delivered by Salmonella.
Collapse
Affiliation(s)
- Larisa I Karpenko
- The Joint-Stock Company Vector Best, The State Research Center of Virology and Biotechnology VECTOR, Novosibirsk Region, 630559 Koltsovo, Russia.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
45
|
Bazhan SI, Belavin PA, Seregin SV, Danilyuk NK, Babkina IN, Karpenko LI, Nekrasova NA, Lebedev LR, Ignatyev GM, Agafonov AP, Poryvaeva VA, Aborneva IV, Ilyichev AA. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens. Vaccine 2004; 22:1672-82. [PMID: 15068850 DOI: 10.1016/j.vaccine.2003.09.048] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
A synthetic T cell immunogen (TCI) has been designed as a candidate DNA-based vaccine against Human immunodeficiency virus (HIV)-1 using cytotoxic T lymphocytes (CD8(+) CTL) and T-helper lymphocytes (CD4(+) Th) epitopes retrieved from the Los Alamos HIV Molecular Immunology Database. The protein 392 amino acids in length contains about eighty CTL-epitopes, many of which are overlapping and are totally restricted by ten different HLA class I molecules. To be able to detect CTL responses induced by a DNA vaccine in experimental animals, additional epitopes, restricted by mouse and Macaque rhesus major histocompatibility complex (MHC) class I molecules, were included in the target immunogen. The gene encoding the TCI protein was assembled, cloned into vector plasmids and expressed in a prokaryotic and a eukaryotic system. The presence of HIV-1 protein fragments in the immunogen structure was ascertained by ELISA and immunoblotting using panels of HIV-1-positive sera and monoclonal antibodies to p24. It has been demonstrated that DNA vaccine can induce both specific T cell responses (CTL and blast transformation) and specific antibodies in mice immunized with pcDNA-TCI.
Collapse
Affiliation(s)
- Sergei I Bazhan
- The State Research Center of Virology and Biotechnology Vector, 630559 Koltsovo, Novosibirsk Region, Russia.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
46
|
Bazhan SI, Belavin PA, Seregin SV, Danilyuk NK, Babkina IN, Karpenko LI, Nekrasova NA, Lebedev LR, Agafonov AP, Ignat'ev GM, Il'ichev AA, Sandakhchiev LS. Construction of an Artificial Immunogen, a Candidate DNA Vaccine Encoding Multiple CTL Epitopes of HIV-1. DOKL BIOCHEM BIOPHYS 2004; 395:108-10. [PMID: 15253564 DOI: 10.1023/b:dobi.0000025558.70018.4a] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S I Bazhan
- Vector State Research Center of Virology and Biotechnology, Kol'tsovo, Novosibirsk oblast, 630559 Russia
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
47
|
Karpenko LI, Nekrasova NA, Ignat'ev GM, Agafonov AP, Proniaeva TP, Murashev BV, Romanovich AE, Klimov NA, Kozlov AP, Il'ichev AA. [Immune response in oral and rectal immunization by the attenuated strain of salmonella carrying the HIV DNA-vaccine]. Vopr Virusol 2003; 48:16-20. [PMID: 12945201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
The recombinant strain of Salmonella typhimurium SL7207/pBMC-env, carrying a plasmid containing the gene of protein HIV-1 gp-160, was obtained under the monitoring by CMV-promoter. The above strain was used in the rectal and oral immunization of BALB/c mice. HIV-specific antibodies were detected in serum after a one-time immunization; such antibodies were able to inhibit the viral replication in vitro. Furthermore, the shaping-up of the specific cytotoxic and of proliferative responses was registered. Finally, the rectal immunization by cells of the Salmonella recombinant strain can be regarded as a promising delivery system of DNA-vaccine (pBMC-env), and it is more effective versus the oral immunization variant.
Collapse
|
|
48
|
Karpenko LI, Bazhan SI, Ignat'ev GM, Lebedev LR, Il'ichev AA, Sandakhchiev LS. [Artificial anti-HIV immunogens and methods of their delivery]. Vestn Ross Akad Med Nauk 2003:24-30. [PMID: 12608081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
Elaboration of an anti-HIV vaccine is a highly important task because there is a need to arrest or at least to slow-down the rapid spread of AIDS throughout the world. Regrettably, no attempts to create an effective vaccine resulted in success. Nonetheless, the available data contribute to building up the confidence in that the set purpose can be achieved provided extra resources are found for working out a potential anti-HIV vaccine. The paper contains some results of research conducted by the "Vector" Research Center for Virology and Biotechnology in the field of artificial polyepitope immunogens, which could be potential anti-HIV vaccines, and in the field of creating various system for their delivery. The immunogenic properties of the thus obtained vaccine structures were tested on mice BALB/c. The delivery systems were experimentally demonstrated to ensure the induction of specific antibodies against HIV-1, with such anti-bodies having a virus-neutralizing activity; the above systems also induce the cellular immunity.
Collapse
|
|
49
|
Karpenko LI, Lebedev LR, Ignatyev GM, Agafonov AP, Poryvaeva VA, Pronyaeva TR, Ryabchikova EI, Pokrovsky AG, Ilyichev AA. Construction of artificial virus-like particles exposing HIV epitopes, and the study of their immunogenic properties. Vaccine 2003; 21:386-92. [PMID: 12531636 DOI: 10.1016/s0264-410x(02)00406-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
One of the major problems in the development of successful recombinant vaccines against human immunodeficiency virus (HIV) is that of correct identification of a safe and effective vaccine delivery system with which to induce protective immunity using soluble protein antigens. An original method for constructing artificial immunogens in the form of spherical particles with yeast dsRNA in the center and hybrid proteins exposing epitopes of an infectious agent on the surface is reported. The dsRNA and the proteins were linked with spermidine-polyglucin-glutathione conjugates. Particles exposing HIV-1 epitopes were constructed, and their immunogenicity tested.
Collapse
Affiliation(s)
- Larisa I Karpenko
- The State Research Center of Virology and Biotechnology Vector, The Joint-Stock Company Vector Best 630559, Novosibirsk Region, Koltsovo, Russia.
| | | | | | | | | | | | | | | | | |
Collapse
|
|
50
|
Nikolenko GN, Protopopova EV, Il'ichev AA, Konovalova SN, Karpenko LI, Loktev VB, Poryvaeva VA, Tikunova NV. [Recombinant antibodies to tick-borne encephalitis virus]. Vopr Virusol 2002; 47:31-6. [PMID: 12522967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
A gene encoding the dimeric form of single-chain antibody fragments (scFv) was designed on the basis of the artificial gene coding monomeric scFv to tick-borne encephalitis glycoprotein E. The sequence encoding histidine oligomer was added to 3'-ends of the genes encoding the monomeric and dimeric forms of scFv antibodies. Escherichia coli strains were constructed for the production of monomeric and dimeric antibodies. These antibodies were purified using Ni-NTA resin. The specificity of the purified monomeric and dimeric antibodies in the binding reaction with tick-borne encephalitis virus was shown by ELISA and Western-blot analysis. The identity of glycoprotein E epitope bound by monomeric and dimeric scFv and parental monoclonal antibodies E6B was confirmed by competitive immunoassay.
Collapse
|